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ABSTRACT National epidemiologic data were examined
to determine the eligibility for curative therapy in tracheal
carcinoma. An expert audit of primary tracheal carcinomas
registered from 2000 to 2005 with the Netherlands Cancer
Registry (NCR) included blinded patient data and radiographic
review to assess diagnosis and resectability. Actual treatment
was compared with the opinions of a multidisciplinary panel
(Radboud panel) and a second reviewer. Of 101 NCR-regis-
tered primary tracheal carcinomas, the Radboud panel
diagnosis was metastatic disease or local extension of adjacent
tumors in 34. Seventeen cases were excluded for missing data.
In 50 cases confirmed by panel and a second reviewer, actual
treatment consisted of surgery in 12 (24%), radiotherapy in 29
(58%), endobronchial treatment in 6 (12%), and observation in
3 (6%). Both panel and second reviewer identified 16 addi-
tional surgical candidates, a total of 28 (56%) of 50. Treatment
recommendations of panel and second reviewer disagreed in
four cases (8%). One-third of NCR-registered primary tracheal
carcinomas were misclassified nontracheal primary tumors
involving the trachea. A majority of cases meeting audit cri-
teria for diagnosis and surgical resection was treated with other
modalities. Interreviewer disagreement was small. The audit
of a national cancer registry suggests that incorrect diagnosis
and undertreatment are common in rare airway tumors.
Primary malignancies of the trachea are rare and chal-
lenging tumors. Surgical resection of the involved tracheal
segment is the treatment of choice, and long-term disease-
free survival has been reported after tracheal resection.1–3
Clinical series suggest that at least half of all patients with
primary tracheal carcinoma are surgical candidates.4,5 The
actual treatment of tracheal cancer in the Netherlands as
reported for the period 1989 to 2002 consisted of resection
in only 12% of cases.6 Similar proportions were found in
epidemiologic studies from Denmark and Finland.7,8 The
discrepancy between reported ratios of surgical clinics and
these epidemiologic studies may be partly based on patient
selection. However, some authors suspected a lack of
knowledge and a nihilistic attitude toward the treatment of
tracheal malignancies.7,8
Previous epidemiologic studies contained database
information, but no systematic review of radiographs, to
explain the discrepancy between clinical and epidemiol-
ogic data.7 To determine the proportion of the Dutch
cancer registry patients with tracheal cancer whose radio-
graphic findings are consistent with the diagnosis and who




In a 6-year period from 2000 to 2005, all cases coded for
primary tracheal carcinoma, labeled C33.9 according to the
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International Classification of Diseases for Oncology, 3rd
Revision (ICD-O-3), and reported to the Netherlands
Cancer Registry (NCR), through all nine regional cancer
registries, were selected.9 The main source of notification
is the national archive of pathology reports (Pathologisch
Anatomisch Landelijk Geautomatiseerd Archief, PALGA),
complemented by data from the national hospital discharge
registry with case summaries of all patients. The docu-
mentation of registered tumors is completed by reviewers
at the regional registries who excerpt patient hospital
charts. We received permission for this study from the
national supervisory committee of the NCR. A waiver for
patient consent was obtained with the provision that the
primary care physician would agree to enrollment onto the
study.
Patient Data Collection
We acquired the names and addresses of the primary
care physicians caring for each patient from the NCR
database. All physicians gave permission to include their
patients in the study after a written request. Copies of
patient charts detailing diagnosis and treatment of tracheal
disease were gathered, with additional documentation
from referring physicians or specialists providing second
opinions. Information on patient and clinical characteris-
tics, diagnostic procedures, tumor pathology, and
treatment were entered into a study database. The interval
from first seeking care from a specialist to histological
diagnosis was obtained and termed ‘‘diagnostic delay.’’
Patient charts were searched for documentation of thera-
peutic decisions and potential contraindications to surgical
treatment. Thoracic or otolaryngologic consultation,
where documented, was recorded. To protect confidenti-
ality, data entered the audit anonymized, and panel
members or second reviewers had no access to patient
records or identifiers.
The minimum diagnostic evaluation that was considered
complete consisted of cross-sectional imaging by com-
puted tomography (CT) or magnetic resonance imaging
and bronchoscopy. Cases were excluded if documentation
of evaluation was unavailable or if abnormal findings of
either diagnostic modality were not explained or evaluated.
Diagnostic images were obtained from radiological hospi-
tal archives for each case. From these images, tumor length
and extension to other organs, lymph node enlargement,
presence of metastatic disease, and evidence of potential
comorbid conditions were recorded. Where radiological
tumor length diverged from bronchoscopic descriptions,
the longer length was recorded. Evaluation of liver and
adrenal glands was assumed when a dedicated abdominal
CT was obtained or when both organs were shown on the
chest study.
Audit Case Review
Cases were reviewed by a multidisciplinary panel of
physicians treating tracheal cancer at Radboud University
Nijmegen Medical Centre, Nijmegen, the Netherlands
(Radboud panel). The panel consisted of one pulmonary
physician (H.H.), one cardiothoracic surgeon (A.V.), one
radiologist (L.D.), two radiation oncologists (J.K. and J.B.),
and one surgical head and neck oncologist (H.M.). A sec-
ond review, independent from the Radboud panel, was
provided by a thoracic surgeon with experience in tracheal
carcinoma (H.G.).
For each case, clinical summaries in combination with
CT or magnetic resonance imaging of the trachea and chest
were reviewed. Auditors were provided demographic and
historic information including sex, age, comorbidity, prior
malignancy and treatment, complaints, and excerpts of
available radiographic, endoscopic, pathology, or staging
reports. The team was blinded to the actual treatment.
Audit of the Diagnosis of Primary Tracheal Carcinoma
The audit consisted of two parts, both performed by the
Radboud panel and a second reviewer. The first part
reviewed the primary diagnosis. In the presence of enlarged
mediastinal lymph nodes, the tumor was assumed to be
primary tracheal carcinoma only when the main tumor
mass was located in the trachea, the tracheal tumor was
separate from mediastinal lymph nodes, and no other
radiographic finding indicated the presence of a primary
carcinoma of the lung elsewhere. If the main tumor mass
was centered either in a main stem bronchus or in a dif-
ferent organ adjacent to the trachea, in the esophagus, or in
the larynx, the tumor was assumed to be a local extension
and not primary tracheal carcinoma.
Audit of Treatment
For the second part of the audit, the Radboud panel and
a second reviewer determined resectability and therapeutic
options in each case. Tumors were assumed to be resect-
able when the tumor-bearing tracheal segment could be
removed and reconstructed by primary anastomosis, taking
into account age and body habitus of the patient (between
20% and 50% of the total tracheal length), absence of vital
organ invasion such as the heart or great vessels, and
absence of mediastinal lymph node involvement. Previous
high-dose ([50 Gy) irradiation to the trachea was also
regarded as a contraindication to resection.
Radboud panel findings regarding resectability and
advised management were consensus based, replicating
everyday multidisciplinary oncology practice. The opinion
of the second reviewer was compared with the panel
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assessment. The combined opinion of panel and second
reviewer was compared with actual treatment, marking
cases as surgical candidates only when decided indepen-
dently by both reviews.
Statistical Analysis
Statistical testing was performed with SPSS version 14.0
statistical software (SPSS, Chicago, IL). Continuous vari-
ables were compared with one-way analysis of variance,
and categorical variables were compared with the v2 test.
RESULTS
Diagnosis of Tracheal Cancer
The results from the audit process are depicted in Fig. 1.
Excluding two cases in children and two found at autopsy,
the NCR identified 104 tracheal carcinomas from 51 hospi-
tals in the period 2000–2005. Three cases for which imaging
studies could not be located were excluded from analysis.
Of 101 cases reviewed in the initial audit, 34 carcinomas
(33.7%) were judged to originate from sites other than the
trachea and were thus excluded from further analysis. In 20
(19.8%) of 101, tracheal biopsy findings positive for car-
cinoma originated from a primary tumor elsewhere: the
lung or main stem bronchus with ingrowth into trachea in
14 cases (squamous cell carcinoma [SCC] in 7, small cell
carcinoma in 3, large cell carcinoma in 3, and adenocar-
cinoma in 1), the esophagus in three (all SCC), and the
larynx in three (SCC in two and carcinoma-in-situ in one).
One of these laryngeal tumors had been surgically resected.
In the other 14 (13.9%) of 101 cases, mediastinal lym-
phadenopathy extended into the tracheal lumen or caused
malignant stricture without detectable primary tumor. These
cases were regarded as a metastatic malignant stricture.
Missing Information
Seventeen cases, none resected, were excluded as a
result of insufficient clinical information. There was no
staging for distant metastasis in seven cases; in three, the
chest CT was incomplete, and in four, potential metastasis
identified by CT was not evaluated.
Resectability could not be determined in six cases.
Extent and length of an adenoid cystic carcinoma (ACC)
was unclear in two, and in the other cases, bronchoscopy
was not performed or was not documented, the extent of
esophageal invasion was not evaluated, or enlarged medi-
astinal lymph nodes did not undergo biopsy.
Operability was uncertain as a result of important car-
diovascular disease in two cases and locally advanced
synchronous bronchial carcinoma in two others.
Patient Characteristics and Disease Manifestation
Characteristics of the remaining 50 cases are shown in
Table 1. Mean age was 63.7 years (range 32–85 years).
Two of 15 prior airway cancers were synchronous bron-
chial cancer. Two other cases had synchronous colon
carcinoma and papillary thyroid carcinoma, respectively.
Cases of ACC were younger (mean 57.9 years vs.
66.4 years, P = .047), more often female (61.5% vs.
37.0%, NS), less often smokers (58.3% vs. 91.7%,
P = .017), and had fewer prior airway malignancies (0%
vs. 48.1%, P = .002) than those with SCC.
The four most common presenting symptoms were
dyspnea, cough, hemoptysis, and stridor. Of 50 patients, in
47 (94.0%) one or more, and in 36 (72%) two or more of
these symptoms were present. One tracheal carcinoma
manifested as asymptomatic concomitant with bronchial
cancer during workup of a nasal inverted papilloma. Ten
patients were first seen at a tertiary center. Referral to
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FIG. 1 Depiction of the audit process. Patient is noted as resectable
only when indicated by both the review by the Radboud panel and the
second reviewer. The actual treatment (blue balloons) is compared
with the assessment of the audit (white balloons) in 50 patients with
primary tracheal carcinoma (P = .005). Surface area of balloons
represents the number of patients in each group
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for a second opinion, while 13 (26%) were not referred.
Median diagnostic delay was 9 days (mean 24 days) and
ranged from 0 to 285 days.
Diagnostic Procedures
Diagnostic tests and tumor histology are summarized in
Tables 2 and 3. Tumor and tracheal length were measured
by endoscopy by the treating physician in 14 (28%) of 50
cases. In six cases, cervical nodal invasion was found on
CT and confirmed by biopsy. In five cases (10%), chest CT
showed pulmonary metastases. Abdominal CT revealed
liver metastases in one case.
Actual Treatment
Primary treatment was radiotherapy in 29 (58%) of 50
cases, combined with endobronchial treatment in 8, chemo-
therapy in 3, and both endobronchial treatment and
chemotherapy in 5. The radiation dose was \39 Gy in 6
cases, between 39 and 59 Gy in 4, [59 Gy in 19,
and C70 Gy in 6. Surgical resection was performed in 12
(24%) of 50. Resection was preceded by endoscopic debul-
king in four cases. Postoperative adjuvant radiotherapy was
administered at a dose of 39 to 59 Gy in four cases
and [59 Gy in five. In 6 (12%) of 50 cases, primary treatment
consisted of endobronchial resection. In 3 (6%) of 50 cases,
only supportive care had been provided. Seven (54%) of 13
patients with ACC underwent surgical airway resection.
Radboud Panel Opinion
In 10 cases without distant metastases, the tracheal
tumor was considered unresectable because of mediastinal
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1–4 weeks 15 31
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3–6 months 9 18
6–12 months 2 4






a In 49 patients who had symptoms
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invasion in 5, excessive length in 4, and dissemination
during previous thyroidectomy in 1. The panel regarded
three cases as resectable but inoperable as a result of
advanced age or local recurrence of a peripheral lung
cancer. In 31 (62%) of 50 primary tracheal carcinoma, the
panel advised surgical tracheal resection with curative
intent.
Opinion of Second Reviewer
In 4 (8%) of 50 cases, the individual thoracic surgeon
differed from the panel regarding tumor resectability. The
second reviewer judged three cases considered resectable
by the panel as unresectable because of prior cervicome-
diastinal radiation. The Radboud panel considered one case
judged resectable by the second reviewer as unresectable as
a result of lymphadenopathy. Thus, there were 28 candi-
dates for resection as determined by both the Radboud
panel and the second reviewer.
Potential Surgical Candidates
Of 28 potential surgical candidates, actual treatment in
16 cases (57%) consisted of other modalities: radiotherapy
in 11, endobronchial therapy in 4, and supportive care in 1.
Only 12 (43%) of 28 of surgical candidates actually
underwent surgical resection. Age, histological type, and
tumor length in these groups are listed in Table 4. Con-
traindications to surgery that were stated in the medical
chart are listed in Table 5. Surgical consultation had been
obtained in half (8 of 16) of surgical candidates who had
not undergone resection.
If we assume that none of the 17 cases excluded from
review as a result of insufficient clinical information would
have been a candidate for tracheal resection, 28 (42%) of
67 of cases would have been surgical candidates, as
opposed to the actual resection rate of 12 (18%) of 67
(P = .003).
DISCUSSION
An audit review of the NCR found metastases to the
trachea in one-third of cases registered, and therefore in our
view misclassified as primary tracheal carcinoma. Our
study further finds that fewer than half of all patients with
resectable tumors undergo surgical resection. These find-
ings highlight the limited validity of epidemiologic data for
this and other rare diseases that are reported to the registry
without radiologic or histologic review. More importantly,
the audit points to problems in the clinical care of patients
with uncommon tracheal tumors.
The concept of unsolicited panel and radiographic
review of all registered cases of a certain type of tumor in
one country in a designated period is unique in its design
and to our knowledge has never been described before.
TABLE 2 Diagnostic and dissemination tests
Test n %
Seen on chest X-ray
Yes 14 28
No 36 72















CT liver and adrenal glands 29 58
PET scan 14 28
Scintigraphy 6 12
Esophagoscopy 6 12
US abdomen 5 10
Histology neck node 5 10
MRI of the chest 4 8
US neck 4 8
CT or MRI brain 3 6
Endoesophageal US 3 6
Mediastinoscopy 2 4
High-resolution chest CT 2 4
Swallow X-ray 1 2
CT computed tomography, PET positron emission tomography, US
ultrasound, MRI magnetic resonance imaging






Large cell carcinoma 3 6
Adenocarcinoma 2 4
Small cell carcinoma 1 2
SCC squamous cell carcinoma, ACC adenoid cystic carcinoma
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Although external auditing of blinded and abstracted data
by a panel of experts itself is subject to limitations, this
method approximates the concept of multidisciplinary on-
cologic review by local experts adopted for common
tumors in everyday practice. Treatment advice of our panel
review is furthermore reproducible: the interreviewer dis-
agreement between the Radboud panel and the second
reviewer was small (8%). In rare diseases such as tracheal
tumors, however, the pool of experts is small and often not
local. The emphasis on local surgical assessment and care
may imply a potentially profound difference in the indi-
cations for surgical therapy and the outcome of individual
patients.
The high proportion of misclassified tracheal carcino-
mas in the NCR suggests that the registration process for
uncommon tumors may be improved. Errors in this clas-
sification consisted of a misattribution of tumors
originating from adjacent organs or mediastinal lymphad-
enopathy with invasion of the airway wall to the trachea.
Results of any biopsy of tumor from the trachea are
reported to the NCR as tracheal cancer through the direct
link with the national pathology database (PALGA). The
final registration in the NCR database, however, involves a
review of the patient medical chart. Some of the misdiag-
noses may therefore have occurred when the tumor site of
origin was misclassified in the report to the NCR. A ret-
rospective review may correct the database error, but not
the implications for patient care.
Three other epidemiologic studies of national cancer
registry data also found misclassified tracheal carcinomas.
A Finnish study found 36 metastatic tracheal lesions
among 133 registered primary carcinomas (27.1%), while a
Danish audit excluded 16 misclassified tumors from 130
registered cases (12.3%).7,10 In a review of the American
Surveillance, Epidemiology, and End Results (SEER)
database, Bhattacharyya disregarded cases with distant
metastasis and excluded an additional 7 (7.1%) of 99 cases
with carcinoma-in-situ or unclear pathology.11 None of
these studies, however, included a complete radiological
review and thus may have underestimated the proportion of
misclassified metastatic tumors. Conversely, misclassifi-
cation could also have occurred by labeling cases of
primary tracheal cancer as metastatic bronchial, laryngeal,
esophageal, or thyroidal carcinoma. This error, however, is
expected to occur less frequently because the registry is
linked to the site of biopsy, requiring active intervention by
the responsible physician to change the tumor site.
A critical assessment of our previous study on incidence
and treatment of tracheal carcinoma, also on the basis of
the files of the NCR but without review of radiographs,
now suggests that the incidence of this disease in the
Netherlands is overestimated and probably closer to .1 in
every 100,000 persons per year.6 The high rate of small cell
carcinoma in our previous study (11.0%), regarded as a
marker of contamination with metastatic disease, was
likely caused by the misclassification of peripheral bron-
chial carcinomas.12 We estimate that ACC accounts for
approximately one-quarter of tracheal cancers. In surgical
series, ACC is encountered in 40% to 60% of cases.13–15
The reported incidence of SCC lies fairly constant at
TABLE 4 Patient and tumor characteristics in surgical and nonsurgical candidates
Candidates N Age (year) Histological type (%) Tumor length (cm)
Mean Range SCC ACC Cd Other Mean Range
Surgical candidates 28 61.4a 32–80 32.1 35.7 14.3 17.9 3.0b 1.0–5.5
Resected 12 57.8c 37–75 33.3 58.3 8.3 0 2.8d 1.5–5.5
Not resected 16 64.3c 32–80 31.3 18.8 18.8 31.3 3.3d 1.0–5.2
Nonsurgical candidates 22 66.5a 46–85 81.8 13.6 0 4.5 5.5b 1.4–12.0
Overall 50 63.7 32–85 54.0 26.0 8.0 12.0 4.2 1.0–12.0
SCC squamous cell carcinoma, ACC adenoid cystic carcinoma, Cd carcinoid
a P = .165
b P \ .0001
c P = .190
d P = .358
TABLE 5 Documented reasons for nonsurgical management in 16
nonresected surgical candidates
Reason n %
Tracheal process unresectable 7 43.8
Segment too long 2 12.5
Possible ingrowth muscular esophagus 1 6.3
Long dysplastic area in trachea 1 6.3
Not documented 1 6.3
Carcinoid tumor 3 18.8
Patient preference 1 6.3
Not documented 7 43.8
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approximately 50% in both epidemiologic and surgical
series.3,6,16–18 Future epidemiologic studies of tracheal
carcinoma and other tumors of low incidence should
therefore include an audit review of radiographic and,
where feasible, also histologic images.
Our study had important limitations. A retrospective
case review does not include patient contact, physical
assessment, or endoscopic examination. The locoregional
extent of disease, in the context of patient factors such as
age, weight, and neck mobility, is the single most impor-
tant factor determining resectability.2 Despite panel review
of CTs, endoscopy reports were usually brief and often
nondescriptive. Endoscopic measurements of tracheal and
tumor length were missing in 72% of patients. Thus, the
actual resectability rate may be lower than our estimate.
Still, tumor length in potential surgical candidates was well
within the range of resectable disease, and differences of
mean and range of tumor length between patients treated
with resection and additional surgical candidates were
small (mean 2.8 and 3.3 cm, respectively).2 A further
potential source of error in our study was the determination
of operability status based on available evidence in the
patient’s medical chart. However, the Radboud panel
excluded four cases in which the absence or presence of
medical contraindications to surgery could not be deter-
mined, even though patients’ disease is rarely declared
unresectable as a result of medical contraindications.2 As
depicted in Table 5, no medical contraindications were
identified in any of the 16 additional surgical candidates
who did not undergo surgical resection.
Our results provide additional evidence that half of all
patients with primary tracheal cancer are surgical candi-
dates.4,5 The balance is tipped furthest toward resection in
ACC: the Radboud panel judged 10 (77%) of 13 cases to
have resectable disease. Because this national audit was
preceded by epidemiologic studies in Denmark, Finland, and
the United Kingdom with comparable outcome with those in
the Netherlands, these results are likely representative for the
situation in most western European countries.6–8,16
We believe that each patient diagnosed with a tracheal
tumor should be referred to a tertiary oncology center with
multidisciplinary experience in the treatment of tracheal
tumors. Given the rarity of the disease, to warrant sufficient
exposure to malignant tracheal pathology and to maintain
experience, one center per each population of an estimated
10 to 20 million would be optimal. In the Dutch situation,
this would mean one national center. By centralizing the
care for patients with this rare airway tumor, more patients
may be selected for surgical resection, thus potentially
improving outcome. Because this improvement is inferred
but untested, close evaluation would be needed once a
centralized system is implemented to assess the exact
benefit of this new strategy.
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